EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC

Liqianqi Chen, Suihao Zhang, Long Gong, Yucong Zhang

Frontiers in Oncology · 24.05.2024 · 14

DOI: 10.3389/fonc.2024.1404045 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 24.05.2024. Verfasst von Liqianqi Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Jinan University, Shenzhen, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PD-1 inhibitors exhibit efficacy in managing unresectable/metastatic driver gene-negative NSCLC, albeit with potential immune-related adverse events (irAEs). Among these, immune checkpoint inhibitor-associated myocarditis (ICI-M) is rare yet lethal. This study presents the initial successful instance of ICI-M in a lung cancer patient, rescued by low-dose glucocorticoids post-deterioration during treatment. Case summary A 78-year-old male with a medical history of stage IV pT3N2M1 NSCLC underwent four cycles of palliative chemotherapy, resulting in stable disease (SD). Subsequent to declining further chemotherapy, the patient was transitioned to a targeted therapy regimen comprising Anlotinib in conjunction with PD-1 inhibitor immunotherapy. On the 26th day post-administration of the PD-1 inhibitor, the patient manifested Grade 2 immune-mediated myocarditis. Treatment encompassing 1mg/kg methylprednisolone combined with immunoglobulin shock therapy was initiated for 3 days, achieving symptomatic control. Nonetheless, upon tapering methylprednisolone dosage to 4–8mg/3–4d, the condition deteriorated, necessitating transfer to the intensive care unit. Methylprednisolone dosage was escalated to 80mg/day for 3 days, followed by gradual reduction by one-third to two-thirds weekly, culminating in the patient’s safe discharge from the hospital.

Conclusion

Immune-related myocarditis linked to checkpoint inhibitors is often managed effectively with high-dose glucocorticoid therapy. However, in Asian populations, low-dose glucocorticoids are increasingly utilized for salvage therapy, yielding favorable outcomes and improving prognosis compared to European populations.

Schlagwörter

Stichwörter der Autor:innen

PD-1 inhibitorimmune myocarditislow-dose glucocorticoidmethylprednisolonenon-small cell lung cancer

Autor:innen und Institutionen

  • The Second Clinical Medical College, Jinan University, Shenzhen, China.
  • Department of Cardiology, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China.
  • Department of Radiotherapy, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China.

Förderung

  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Chen, L., Zhang, S., Gong, L., & Zhang, Y. (2024). Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1404045

Vancouver

Chen L, Zhang S, Gong L, Zhang Y. Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1404045

BibTeX
@article{Chen2024,
  author = {Chen, Liqianqi and Zhang, Suihao and Gong, Long and Zhang, Yucong},
  title = {Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1404045}
}
Kostenlos starten →